growth arrest-specific factor 6

August 9, 2019September 10, 2019

AVB-500 Plus Chemotherapy More Effective Than Chemo Alone in Platinum-resistant Patients, Early Trial Data Suggest

News

Aravive‘s experimental treatment, AVB-500, in combination with chemotherapy appears to be more effective than chemotherapy alone at treating platinum-resistant ovarian cancer, preliminary results from a first group of patients taking ... Read more

August 22, 2018August 22, 2018

Aravive Biologics’ Therapy Earns FDA’s Fast Track Designation to Treat Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to AVB-S6-500 as a potential therapy for chemotherapy-resistant ovarian cancer, Aravive Biologics, the therapy’s developer, announced. Fast track designation is given ... Read more